Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis
Journal of Oral Pathology & Medicine · 2024
DOI: 10.1111/jop.13542 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Oral Pathology & Medicine, 2024. Verfasst von Ao-Bo Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Cent…. Hauptthemen laut MEDLINE: Ameloblastoma, Proto-Oncogene Proteins B-raf, Bayes Theorem, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China, National clinical keydiscipline construction project.
Abstract (Originalsprache)
Objective
This Bayesian network meta‐analysis was performed to analyze the associations between clinicopathological characteristics and BRAF mutations in ameloblastoma (AM) patients and to evaluate the diagnostic accuracy. Materials and Methods Four electronic databases were searched from 2010 to 2024. The search terms used were specific to BRAF and AM. Observational studies or randomized controlled trials were considered eligible. The incidence of BRAF mutation and corresponding clinicopathological features in AM patients were subjected to Bayesian network analyses and diagnostic accuracy evaluation.
Results
A total of 937 AM patients from 20 studies were included. The pooled prevalence of BRAF mutations in AM patients was 72%. According to the Bayesian network analysis, BRAF mutations are more likely to occur in younger (odds ratio [OR], 2.3; credible interval [CrI]: 1.2–4.5), mandible site (OR, 3.6; 95% CrI: 2.7–5.2), and unicystic (OR, 1.6; 95% CrI: 1.1–2.4) AM patients. Similarly, higher diagnostic accuracy was found in the younger, mandible, and unicystic AM groups.
Conclusions
The incidence, risk, and diagnostic accuracy of BRAF mutation in AM were greater in younger patients, those with mandible involvement, and those with unicystic AM than in patients with other clinicopathological features. In addition, there was a strong concordance in the diagnostic accuracy between molecular tests and immunohistochemical analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Bi…
- Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), Beijing, China.
- Department of stomatology, Shandong Public Health Clinical Center, Jinan, Shandong, China.
- Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China.
ORCID-Profile: Ao-Bo Zhang, Li-Sha Sun, Tie-Jun Li
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- National clinical keydiscipline construction project
Zitieren
APA
Zhang, A. B., Zhang, J. Y., Liu, Y. P., Wang, S., Bai, J. Y., Sun, L. S., & Li, T. J. (2024). Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13542
Vancouver
Zhang AB, Zhang JY, Liu YP, Wang S, Bai JY, Sun LS, et al. Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis. Journal of Oral Pathology & Medicine. 2024. doi:10.1111/jop.13542
BibTeX
@article{Zhang2024,
author = {Zhang, Ao-Bo and Zhang, Jian-Yun and Liu, Yu-Ping and Wang, Shuo and Bai, Jia-Ying and Sun, Li-Sha and Li, Tie-Jun},
title = {Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis},
journal = {Journal of Oral Pathology & Medicine},
year = {2024},
doi = {10.1111/jop.13542}
}
EUVIMED